Foundation Medicine Inc

Foundation Medicine — Investor Presentation (January 2014)

28 slides from Foundation Medicine's investor presentation, Jan 13, 2014

  1. Slide 1: The Molecular Information Company

    Slide 1: The Molecular Information Company

    Exhibit 99.2 Exhibit Foundation The Molecular 99.2Medicine Information Company

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward These Such the updated and All FoundationOne inability Foundation Medicine’s Any except 2©2013 market forward-looking the forward-looking forward slides as Foundation delivery version of Looking required size Foundation subsequent Medicine’s and looking for Heme of the Statements by Foundati

  3. Slide 3: Our Vision

    Slide 3: Our Vision

    OurFoundation At 3©2013 Vision Foundation Medicine, Medicine, we are Inc.leading a transformation in cancer care, where each patient’s treatment is informed by a deep understanding of the molecular changes that contribute to their disease.

  4. Slide 4: 2013: A Year of Rapid Progress

    Slide 4: 2013: A Year of Rapid Progress

    2013: A$121 >9,000 Approximately Published Launched Raised Expanded Named 4©2013 Foundation clinical aYear “Best FoundationOne 16 keymillion to apeer-reviewed Of BioPharma new tests Place $29 Rapid Medicine, facility million delivered intoSeptember Progress Work” Heme relationships and revenue manus

  5. Slide 5: Translating Cancer Genomes into Actionable Information

    Slide 5: Translating Cancer Genomes into Actionable Information

    Translating Cancer Gene Delivering 5©2013 Alterations Foundation Cells Genesand Each integrating Cancer’s Medicine, actionable Genome Inc. comprehensive molecular information into routine treatment of cancer

  6. Slide 6: FMI BioPharma: Every Cancer Cell Tells a Story

    Slide 6: FMI BioPharma: Every Cancer Cell Tells a Story

    FMI BioPharma Molecular Every Sticky User >18 BioPharma >90 Value Ordered Clinical 6Future alliances Value interface delivered Dataset experience opportunities byInformation Thesis: thousands signed Adds tothrough clinical translate for Three to inphysicians/pharma of Value Platform cancer trials te

  7. Slide 7: Case Presentation

    Slide 7: Case Presentation

    7Case Presentation

  8. Slide 8: Case Presentation: Non-Small Cell Lung Cancer / CUP

    Slide 8: Case Presentation: Non-Small Cell Lung Cancer / CUP

    CASE2012, “Non-Small May 8©2013 PRESENTATION Foundation 58 Cell y.o.Lung female Medicine, Cancer”/Cancer presented Inc. withOfnew Unknown onset ofPrimary seizures(CUP) and was diagnosed with stage IV lung adenocarcinoma with brain metastasis

  9. Slide 9: Case Presentation: Initial Course

    Slide 9: Case Presentation: Initial Course

    CASE2012, May Initial Brain September PET/CT 9©2013 mass Course PRESENTATION Foundation revealed 2012 58 completely y.o.no metabolically female Medicine, change resected presented inInc. abdominal active with 2 xnew 4mass cmonset left and mid seizures slightly abdominal increased and wasmass diagnos

  10. Slide 10: Case Presentation: Negative Initial Testing, FoundationOne Findings

    Slide 10: Case Presentation: Negative Initial Testing, FoundationOne Findings

    CASE Initial Negative FoundationOne™ Identified Based January Scan May Revealed November 12 ©2013 10 months 2013, revealed molecular on PRESENTATION Foundation 2013, for the no MET durable 2012, 2013, PET/CT evidence EGFR findings aPET/CT amplification 40% testing crizotinib PET/CT testing response

  11. Slide 11: FoundationOne Report: Crizotinib, MET inhibitor

    Slide 11: FoundationOne Report: Crizotinib, MET inhibitor

    FoundationOne Crizonib, 11 METi Report ©2013 Foundation Medicine, Inc.

  12. Slide 12: FoundationOne Results and Takeaways

    Slide 12: FoundationOne Results and Takeaways

    FoundationOne Takeaways Results Crizotinib Suggests Patient ©2013 12 Foundation with recently led benefit commenced tometastatic therapy identified visited of Medicine, FoundationOne with disease symptomatic FMIalteration FDA-approved and Inc. (CUP) is leaving in that and now cost isradiographic not

  13. Slide 13: A 100K Annual Initial Target Market Opportunity

    Slide 13: A 100K Annual Initial Target Market Opportunity

    A 100K Annual ~ Initial Potentially Additional US ~2M ~100K ~1M ©2013 13Major Annual Solid use Foundation Heme Target new New inopportunities + expanding Prevalence patients refractory Heme Market Market Medicine, annually Opportunity to for =cases ~2 related ~5M FoundationOne™ million except Inc. p

  14. Slide 14: Rapid Adoption of FoundationOne

    Slide 14: Rapid Adoption of FoundationOne

    Tests 4,000 (unaudited) 1,000 1,140 1,500 1,626 2,000 2,500 2,577 3,000 3,500 500 492 0Q Rapid ©2013 142-12 244 Reported 3,750 878 Adoption adoption Q3-12 Foundation Q4-12 to bolstered Ofordering Medicine, FoundationOne Q1-13byphysicians Q2-13 growing Inc. Q3-13 salesQ4-13 team and repeat orders

  15. Slide 15: Targeted Tests Are Inadequate for Individual Diagnostic Needs

    Slide 15: Targeted Tests Are Inadequate for Individual Diagnostic Needs

    TargetedFoundation Individual ©2013 15 Diagnostic and panelMedicine, Model tests focused Is Inc. Inadequate on one or a group of genes do not reflect the full spectrum and evolving understanding of cancer

  16. Slide 16: Legacy Diagnostic Tools Miss Genes and Alterations

    Slide 16: Legacy Diagnostic Tools Miss Genes and Alterations

    Legacyalterations Non-Small Genes Alterations Many Gene Percentage of cases with ©2013 with Foundation Diagnostic Cell Traditional Actionable Alterations, Lung can Tools Medicine, be Cancer Alterations Gene Actionability addressed MissMarkers Example Inc. Therapeutic 16 with Unknown Commonly (2012)

  17. Slide 17: You Cannot Treat What You Do Not Understand

    Slide 17: You Cannot Treat What You Do Not Understand

    foundationOne 05Number Focal STK11 RB1 CDKN2B CDKN2A KRAS EGFR TP53 200 150 100 You MYC MDM2 MCL1 cannot PTPRD CDK4 LRP1B NF1 RICTOR ERBB2 ©2013 ALK NKX2_1 SOX2 PTEN Non-Small 57% DNMT3A CCNE1 SMAD4 Foundation APC you ATM do FGFR1 AKT2 4% Inc. BRAF Medicine, Base CCND3 NOTCH1 TET2 MET Insertions/del

  18. Slide 18: Current Esoteric Testing Model Is Unsustainable

    Slide 18: Current Esoteric Testing Model Is Unsustainable

    Current Esoteric Specific Reference Special Initial Hospital Time Especially ©2013 Time diagnostic Foundation stains, Model Lab molecular Lab Unsustainable TimeFISH, Broken work-up tests: Medicine, HER2, For KRAS, forPhysicians ER, Payors Inc.BRAF, PR, 18Total EGFR, &EGFR, Payers Costs etc…etc…

  19. Slide 19: The Breakthrough Solution: FoundationOne

    Slide 19: The Breakthrough Solution: FoundationOne

    Themajor Breakthrough Less Ordered Laboratory All Base Insertions Copy 236 Rearrangements Includes +169 +265 >99% ©2013 19 Genes FMI Time, substitutions genes number sensitivity Foundation by additional Solution: classes and Cost developed Oncologist foralterations Breadth deletions DNA RNA and and

  20. Slide 20: Interactive Cancer Explorer (ICE)

    Slide 20: Interactive Cancer Explorer (ICE)

    ICE:decisions consultation Delivers references Enables Developing enable outcomes Provides inform Creates Building team Interactive care ©2013 20 Creating based sharing physician Foundation aphysicians FoundationOne additional dedicated community data and Cancer in expanding with Bay And while clini

  21. Slide 21: Diversity of Alterations Confers Actionability

    Slide 21: Diversity of Alterations Confers Actionability

    Diversity, 82% linked FDA Open confers A information by FoundationOne patients treatment Dataset: ©2013 21 maximum other of approved clinical to: Foundation FoundationOne greater who 3,936 available status Actionability would of lack trial qualifying targeted likelihood 31% Experience provides quogo

  22. Slide 22: Pharma Insights and Collaborations

    Slide 22: Pharma Insights and Collaborations

    PharmaFoundation Insights Resurrected Enhanced Created Enabled Evolving Continues ©2013 22 Solutions combo delivered new to clinical tobroad lagging inform target Tx–trial have strategic opportunities Medicine, discovery/ Partner or enhancements design failed collaborations Ofassets Inc. validation

  23. Slide 23: Case Presentation: AstraZeneca

    Slide 23: Case Presentation: AstraZeneca

    CASE December AstraZeneca FMI September AZ ©2013 23 announced Analysis partnered PRESENTATION Foundation 2011 2013 identifies announced with the initiation Medicine, AZato that new conduct of its path Inc. two oral for retrospective Phase PARP olaparib 3inhibitor, studies analysis inolaparib, ovaria

  24. Slide 24: Reimbursement Strategy and Payor Engagement

    Slide 24: Reimbursement Strategy and Payor Engagement

    Reimbursement Analytic Setting leading for and cancer Payor Early payor development published peer-reviewed Comprehensive ©2013 24 test performance and relationship Engagement centers Foundation validation industry- benchmark Validation expansive in economic conferences journals and Strategy Driving

  25. Slide 25: Key Studies Driving Adoption

    Slide 25: Key Studies Driving Adoption

    Adoption Key Studies HER2 Completed Fusion ALK “Decision In-process Pan NSCLC FoundationOne Phase Pediatric Rare Randomized Planned Earlier Initial ©2013Negative drivers Tumors FISH 1data FISH Stage Concordance Foundation Analytic Matched (BATTLE Relapsed & Impact” from –Reimbursement –Trial, Diseas

  26. Slide 26: Financial Summary: Quarter Ended September 30, 2013

    Slide 26: Financial Summary: Quarter Ended September 30, 2013

    Financial Quarter 2013 Revenue Cost Sales General Research Total Ended ©2013 of 2012 costs and Q3 Foundation revenues Ended and $8,208 and Summary marketing with 2013 and administrative development September expenses $138M $2012 2,858 3,037 Medicine, 3,038 in 1,791 $19,328 $19,322 cash 30, 849 6,988

  27. Slide 27: 2014 Milestones and Guidance

    Slide 27: 2014 Milestones and Guidance

    2014 Milestones 22,000 $52–58 Product Expansion Additional ©2013 27 –Foundation million enhancements: 25,000 of Interactive FoundationOne total clinical AndMedicine, revenue Guidance Cancer reports –Inc. Explorer 1H delivered 2014features and outcomes capabilities – 2H 2014

  28. Slide 28: Foundation Medicine: The Molecular Information Company

    Slide 28: Foundation Medicine: The Molecular Information Company

    Foundation The Molecular Medicine Information Company

Source: SEC EDGAR · 8-K filed Jan 13, 2014

More decks from Foundation Medicine Inc